Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 2. Hemolysis and lymphotoxicity assays. (A) Hemolytic activity of FX-compounds (5 μM) was determined by hemoglobin release from whole blood cells after 120 min incubation. Positive controls (=maximum lysis) were treated with 1% SDS. (B) Leukocytes were incubated in the presence of FX-compounds (5 μM) for a period of 48 and 72 h. Viability was analyzed using Calcein-AM and quantified in comparison to DMSO treated controls, which were set to be =100%. Results show data of six different healthy donors. Experiments were performed in triplicates. Values are given as the mean x-fold increase ± standard deviation.
Biomol Ther 2019;27:492~501 https://doi.org/10.4062/biomolther.2018.199
© Biomolecules & Therapeutics